On August 4, 2020, JoinTechCell LLC of the Nearmedic group of companies received its first international patent for the ESVIEF set designed to isolate the stromal-vascular fraction from adipose tissue for use in regenerative medicine. The company patented its product in South Korea. The set passed all the necessary examination resulting in the positive decision to grant a patent.
ESVIEF is a disposable sterile kit that includes a device for separating cell fractions, and an enzyme for processing the tissue, as well as related products for processing adipose tissue. The device employs the process of step-by-step washing and processing of adipose tissue (lipoaspirate) with an enzyme in order to isolate the stromal-vascular fraction in accordance with the protocol.
The final product — stromal-vascular fraction — is used in plastic surgery and reconstructive medicine, orthopedics, traumatology, urology, coloproctology. It is used to repair damaged ligaments and cartilage of articular surfaces, to treat erectile dysfunction and urinary incontinence, and to close cysto-vaginal and rectovaginal fistulas. In plastic surgery and reconstructive medicine, the stromal-vascular fraction is used for the enrichment of lipoaspirate, for the correction of soft tissue defects, dysplasia, post-traumatic and post-operative defects as well as for aesthetic purposes to improve skin conditions.
South Korea is a country having a most advanced and large plastic surgery and cosmetology market, which has long been actively using stromal-vascular fraction in aesthetic medicine and surgery.
«It is difficult for any foreign manufacturer to obtain a patent in South Korea, as the country’s economic policy is aimed at supporting and developing the domestic market. It has its own systems for obtaining stromal-vascular fraction. Therefore, we consider obtaining a patent there as the recognition of the high quality of our product. The ESVIEF kit is compact and easy to use. It meets all the requirements for the safe isolation and storage of cellular material in accordance with the rules and regulations of good practices (GxP). For us, this is a successful first step in entering the international market,» comments Maria Petkova, Director of the Nearmedic group project office and General Director of JoinTechCell LLC.